Core Viewpoint - There are market rumors that Zhou Chenggang, the long-time partner of New Oriental Group CEO Yu Minhong, is under investigation by regulatory authorities for allegedly misappropriating company interests through related-party transactions. This news has not been officially announced yet, and New Oriental's response claims it is "purely a rumor" [1]. Group 1 - New Oriental Group's CEO Yu Minhong is reportedly linked to Zhou Chenggang, who is facing allegations of misconduct [1]. - Regulatory authorities have initiated an investigation into Zhou Chenggang regarding potential misappropriation of company interests [1]. - New Oriental's official response categorically denies the allegations, labeling them as rumors [1].

（000333.SZ）涨幅居前，ASMPT（00522.HK）、比亚迪电子（00285.HK）、中芯国际（688981.SH） 跌幅靠前。 其中，港股东方甄选（01797.HK）尾盘高位跳水，收跌20.89%，此前一度涨超23%，全天振幅达 45.41%，成交额为93.85亿港元。 8月19日，港股东方甄选（01797.HK）尾盘高位跳水，收跌20.89%，此前一度涨超23%，全天振幅达 45.41%，成交额为93.85亿港元。 8月19日，港股收盘走低，恒生指数收报25122.9点，跌53.95点，跌幅0.21%；恒生科技指数收报5542.03 点，跌37.15点，跌幅0.67%。 恒生指数成分股中，中升控股（00881.HK）、华润啤酒（00291.HK）、翰森制药（03692.HK）涨幅居 前，中国生物制药（01177.HK）、药明康德（603259.SH）、比亚迪电子（00285.HK）跌幅靠前；恒生 科技指数成分股中，同程旅行（00780.HK）、地平线机器人-W（09660.HK）、美的集团 来源：滚动播报 （来源：银柿财经） ...

对此，新东方创始人俞敏洪回应新浪科技称：彻底的谣言。 责任编辑：何俊熹 新浪科技讯 8月19日下午消息，今日港股尾盘，东方甄选快速跳水跌20%，此前一度涨23%。消息面 上，网传新东方集团CEO周成刚被立案调查。 ...

Market Performance - The Hang Seng Index closed down by 0.21% and the Hang Seng Tech Index fell by 0.67% [1] - Oriental Selection experienced a significant drop, closing down over 20% after reaching a peak increase of 23% during the day [1] Biopharmaceutical Sector - Biopharmaceutical stocks continued to decline, with Gilead Sciences-B dropping over 15%, Peijia Medical-B down over 8%, and Hengrui Medicine falling over 5% [1] Other Notable Stocks - Zhihu saw a notable increase, rising over 23% [1]

Market Performance - The Hang Seng Index closed down by 0.21% [1] - The Hang Seng Tech Index fell by 0.67% [1] Company Movements - Oriental Selection experienced a significant drop, closing down over 20% after a peak increase of 23% during the day [1] - Biopharmaceutical stocks continued to decline, with Genscript Biotech Corporation (歌礼制药-B) dropping over 15%, Peijia Medical (派格生物医药-B) down over 8%, and Hengrui Medicine (恒瑞医药) falling over 5% [1] - Zhihu saw a notable increase, rising over 23% [1]

Group 1 - The stock price of Dongfang Zhenxuan (1797.HK) experienced a significant increase of over 23% before sharply declining, with a further drop of 20% and a trading volume exceeding 8 billion HKD, resulting in a daily fluctuation of 43% [1] - In the past two months, Dongfang Zhenxuan's stock price surged, with an increase of 85% in July and an additional 144% in August, reaching a new high since February 2023 during intraday trading [3]

东方甄选(1797.HK)在拉升超23%后高台跳水，目前跌幅进一步扩大至20%，日内振幅达43%。 东方甄选最近两个月股价比飙升，在7月份累涨85%后，8月一度再累涨144%。今日盘中股价一度创 2023年2月以来新高。 本文源自：金融界 ...

东方甄选最近两个月股价飙升，在7月份累涨85%后，8月一度再累涨144%。今日盘中股价一度创2023 年2月以来新高。 格隆汇8月19日｜东方甄选(1797.HK)在拉升超23%后高台跳水，目前跌幅进一步扩大至20%，成交额放 大至逾80亿港元，日内振幅达43%。 ...

东方甄选尾盘跳水跌超18%，此前一度涨23%。 ...

（文章来源：每日经济新闻） 每经AI快讯，8月19日，东方甄选尾盘跳水跌20%，此前一度涨23%。 ...